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INTRODUCTION
Alzheimer’s disease (AD) is a progressive
neurodegenerative disease and is the major
cause of dementia in people aged 65 years
and older, affecting approximately 2% of
the population of industrialized coun-
tries (Mattson, 2004). The two primary
histopathological lesions found within the
AD brain are intracellular accumulations
of hyper-phosphorylated tau protein, in
the form of neurofibrillary tangles (NFTs),
and extracellular deposits that are prin-
cipally comprised of β-amyloid peptide
(Aβ) (Adlard and Cummings, 2004). Aβ
has been proposed to be a primary medi-
ator of both the initiation and progres-
sion of disease (Hardy and Selkoe, 2002),
with numerous toxic effects attributed
to its abnormal accumulation within the
neuropil (Karran et al., 2011). While
there remains debate as to which precise
species of Aβ represents the “toxic moiety”
(Selkoe, 2008; Lublin and Gandy, 2010),
the assessment of Aβ from bulk tissue
remains one of the most common analy-
ses conducted within the field, particularly
as it relates to the development of thera-
peutic approaches to this intractable dis-
ease. Throughout our own investigations
it became apparent that different com-
monly used methodologies for the quan-
titation of Aβ would often yield markedly
different results. In this opinion piece we
discuss this notion and present evidence
that highlights the need to exercise caution
when embarking on an analysis of Aβ, or
indeed, when interpreting data from other
papers. We also include some of our own
data where we analyzed a common set of
tissues using standard analysis techniques
that are used in laboratories through-
out the world, including western blot,
ELISA and surface-enhanced laser des-
orption/ionization (SELDI) time of flight
(TOF) mass spectrometry. These analyses
are not meant as a strict side-by-side com-
parison of raw data generated by different
methodologies, but rather, are designed
to emulate different approaches that may
be taken by different laboratories. Thus,
whilst the antibodies, extraction buffers
and other aspects of each technique do
vary—this is the real-life situation where
different approaches are taken to achieve
the same endpoint analysis of Aβ burden.
The resulting differences are striking, and
whilst not necessarily unexpected—it is
important that the field acknowledge this
phenomenon and have an appreciation for
the complexities involved in the apparently
“simple” assessment of Aβ burden.
METHODS
The collection, processing, and storage of
human brains for research purposes was
conducted by the Victorian Brain Bank
Network. Ethics approval was provided
by The University of Melbourne Human
Research Ethics Committee, application
number 941478X, titled “Brain Banking
for Neuroscience Research.”
TISSUE
A cohort of AD (n = 11 M, n = 3 F; 76 ±
2 years), FTD (n = 2 M, n = 3 F; 63 ± 6
years), DLB (n = 1 M, n = 4 F; 81 ± 5
years) and control (n = 7 M, n = 6 F;
73 ± 2 years) cases were obtained from the
Victorian Brain Bank Network. Gray mat-
ter from the frontal and temporal cortices
were sonicated in PBS and centrifuged
at 100,000×g (30min, 4◦C). The pro-
tein content of the collected supernatant
(soluble material) and pellet (insoluble
material) fractions were assessed using
the Pierce BCA protein assay kit accord-
ing to manufacturers recommendations.
The various fractions were subsequently
analyzed using Western blot, ELISA and
SELDI.
Aβ ASSESSMENT METHODS
For ELISA—Aβ levels were determined
using theDELFIA®Double Capture ELISA
as previously described (Ritchie et al.,
2003). For western blots and SELDI-TOF
mass spectrometry, Aβ levels were assessed
as previously published (Adlard et al.,
2008).
STATISTICAL ANALYSIS
A one-way analysis of variance with
a Tukey’s multiple comparison post-hoc
test was utilized to analyse data in
Figures 1A–F, while a paired t-test was
utilized to analyse data in Figure 1G
(GraphPad Prism 5.0 d).
RESULTS
The quantitation of the western blot data
for both insoluble and soluble Aβ species
across the different disease states is shown
in Figures 1A,B. The highest levels of both
insoluble and soluble Aβ species were
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FIGURE 1 | Levels of Aβ detected in brain homogenates from a common
set of human cases. (A,B) Western blot assessment of soluble and
insoluble Aβ burden across the entire cohort of neurological cases and
healthy control cases utilized in this study (C–F) ELISA assessment of soluble
and insoluble Aβ burden across the entire cohort of neurological cases and
healthy control cases utilized in this study (G) A comparison of SELDI mass
spectrometric and ELISA assessment of Aβ burden (Aβ1-40 and Aβ1-42)
across a subset of the cases examined in this study. ∗p < 0.05; ∗∗p < 0.01.
present in the AD cases. This is consistent
with the ELISA data for both insoluble and
soluble Aβ species across the different dis-
ease states, as shown in Figures 1C–F. A
statistical comparison of these data reveal
that the ELISA assay reported significantly
(p < 0.0002) lower levels of insoluble Aβ
than the western blot assay (irrespective
of whether the ELISA values for Aβ1-40
and Aβ1-42 are compared individually
or summed for comparison to the west-
ern blot data). Likewise, the soluble data
reveal the same difference between assay
methodologies (p = 0.002).
Figure 1G shows a comparison of data
generated from a subset of those sam-
ples used above utilizing either SELDI-
TOF MS or ELISA techniques for the
quantitation of Aβ across multiple AD and
DLB cases. A pairwise comparison of the
data generated by the respective meth-
ods for each individual case revealed that
SELDI-TOF MS values for Aβ1-42 were
significantly higher (p < 0.05) than those
obtained using ELISA.
DISCUSSION AND OPINION
In our own studies we had previously
noted that common methodologies
utilized for the assessment of protein levels
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in human biological fluids can return
markedly different results when assess-
ing levels of Aβ peptide. This highlighted
the need for careful methodological con-
siderations when embarking on our
own analyses, or when interpreting the
data reported from different laborato-
ries. To formalize this, we assessed a
common set of tissues using different
techniques including western blot, ELISA
and SELDI-TOF mass spectrometry, and
demonstrated that, under the conditions
utilized, both western blot and SELDI
detected significantly larger pools of Aβ in
human brain specimens than did ELISA
assays. This was true for both soluble and
insoluble fractions of human brain from
a variety of different neurological dis-
ease states including AD, FTD, and DLB
cases, as well as from age-matched con-
trols. Whilst the antibodies, extraction
buffers and other aspects of each tech-
nique did vary in this comparison—this
is the real-life situation where different
approaches are taken in different laborato-
ries to achieve the same endpoint analysis
of Aβ burden. A discussion of these
methodological differences is provided
below.
A similar phenomenon has previously
been reported when examining tissues
from cell culture media (HEK293 human
embryonic kidney cells transfected with a
plasmid vector containing the APP gene
with either the Swedish or Arctic and
Swedish mutations) and from transgenic
animals (harboring the APP gene with
either the Swedish or Arctic and Swedish
mutations), where western blot quanti-
tation revealed a markedly different Aβ
profile than that shown by ELISA assay
(Stenh et al., 2005). The authors deter-
mined that ELISA assays are inefficient at
measuring Aβ oligomers and that different
methodologies are required for the anal-
ysis of soluble Aβ. The data in this study
are consistent with the over-arching find-
ing of this previous report, and clearly
demonstrate thatWestern blot and SELDI-
TOF mass spectrometry are more sensi-
tive techniques that detect a larger pool
of Aβ in the human brain than does
ELISA. Furthermore, western blot and
SELDI offer the advantage that more infor-
mation on the species of Aβ being quan-
titated are provided as a function of the
methodology, where molecular weight is
used to discriminate the various Aβ species
present in a given sample. This represents
perhaps one of the biggest advantages of
these techniques over ELISA, which only
provides an analysis of total immunore-
activity to a particular epitope within a
sample, with no accounting for poten-
tial cross-reactivity with other proteins.
This latter point is an important caveat,
as data generated by ELISA, as with the
other methodologies described, is depen-
dent upon the specific antibodies utilized
within the assay. There are a multitude of
different antibodies that have been gen-
erated against different epitopes of the
Aβ protein, and these may give differ-
ent results when used in these assays.
Likewise, as noted above, the specificity of
the antibodies to a given target is critical,
and is not always optimal when analysing
biological samples. In the case of some
commercial ELISA kits, the precise anti-
bodies utilized (in addition to the extrac-
tion buffers that can liberate different
pools of Aβ depending upon their com-
position) may also be proprietary, leav-
ing the user essentially blind as to what
species of Aβ they are specifically measur-
ing. This may lead to a situation where
the same samples measured using different
ELISA kits provide very different quantita-
tive results. This is a phenomenon that has
been previously reported by Bjerke et al.
(2010), who also noted that the source and
quality of the Aβ utilized as a standard
within the various ELISA kits often varies
and may provide a source of variance that
limits the cross-comparison of data gen-
erated using different ELISA kits. They
also demonstrate that there are numer-
ous confounding factors, other than the
use of ELISA, in the analysis of Aβ from
patient populations (the majority which
result from the inherent properties of the
Aβ protein itself).
The use of ELISA assays has become
common-place in the AD field, repre-
senting the default approach to assay Aβ
from a variety of biological fluids. The
data presented in this paper, together with
previous anecdotal and literature reports,
however, suggest that the isolated use of
ELISA for the quantitation of Aβ may be
an insufficient and/or flawed approach. At
a minimum, the reliance on ELISA data
may result in an under-representation of
the total Aβ protein levels present in a
sample or, in the worse-case scenario, lead
to a misinterpretation of data resulting
from clinical trials where the assessment of
efficacy of a given compound is the move-
ment in a particular Aβ species, whichmay
or may not be within the select “pool” of
Aβ detected by an ELISA assay. This same
caveat is also applicable to western blots
and SELDI techniques, which are inher-
ently reliant on discrete antibodies for
their methods of detection. The difference,
however, is that these latter techniques
generally do not use proprietary antibod-
ies and inherently provide a greater degree
of detail on the precise Aβ species being
examined. As the field continues to move
forward, and our understanding of the rel-
ative pathogenicity of different Aβ species
crystalizes, it is becoming apparent that
the generic “bulk” assessment of Aβ bur-
den is not sufficiently rigorous to provide
the appropriate in-depth characterization,
from both a basic science and a clini-
cal perspective, that is required in patient
populations. The development of new
methodologies is critical, and more pre-
cise techniques such as mass spectrometry,
which allows for the precise differentia-
tion and quantitation of relevant analytes
in a given sample, are now emerging as
the preferred method for the critical anal-
ysis of Aβ from biological samples. Whilst
these methods have their own limitations,
in terms of cost, through-put and accessi-
bility to the necessary infrastructure, their
advantages are clear. Until such techniques
become a more readily viable alternative
for the field, the discussion and data pre-
sented in this paper highlight the need for
a more rigorous approach to the assess-
ment of Aβ that utilizes more common
technologies such as western blot.
ACKNOWLEDGMENTS
We thank Mikhalina Dombrovskaya,
Elysia Robb, Keyla Perez, and Katrina
Laughton for their technical assistance
with generating the data in the paper.
The authors of this manuscript are sup-
ported by the National Health andMedical
Research Council and the Australian
Research Council. Human tissues were
received from the Victorian Brain Bank
Network, supported by the Mental
Health Research Institute, Alfred Hospital,
Victorian Forensic Institute of Medicine,
The University of Melbourne, and funded
Frontiers in Aging Neuroscience www.frontiersin.org August 2014 | Volume 6 | Article 203 | 3
Adlard et al. Different efficiencies in amyloid detection
by Australia’s National Health andMedical
Research Council, Helen Macpherson
Smith Trust, Parkinson’s Victoria and
Perpetual Philanthropic Services. In addi-
tion, the Florey Institute of Neuroscience
andMental Health acknowledge the strong
support from the Victorian Government
and in particular the funding from the
Operational Infrastructure Support Grant.
REFERENCES
Adlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier,
E., Robb, E., Cortes, M., et al. (2008). Rapid
restoration of cognition in Alzheimer’s transgenic
mice with 8-hydroxy quinoline analogs is associ-
ated with decreased interstitial Abeta. Neuron 59,
43–55. doi: 10.1016/j.neuron.2008.06.018
Adlard, P. A., and Cummings, B. J. (2004). Alzheimer’s
disease–a sum greater than its parts? Neurobiol.
Aging 25, 725–733. discussion 743–726. doi:
10.1016/j.neurobiolaging.2003.12.016
Bjerke, M., Portelius, E., Minthon, L., Wallin,
A., Anckarsäter, H., Anckarsäter, R., et al.
(2010). Confounding factors influencing
amyloid Beta concentration in cerebrospinal
fluid. Int. J. Alzheimer’s Dis. 2010:986310. doi:
10.4061/2010/986310
Hardy, J., and Selkoe, D. J. (2002). The amyloid
hypothesis of Alzheimer’s disease: progress and
problems on the road to therapeutics. Science 297,
353–356. doi: 10.1126/science.1072994
Karran, E., Mercken, M., and De Strooper, B. (2011).
The amyloid cascade hypothesis for Alzheimer’s
disease: an appraisal for the development of ther-
apeutics. Nat. Rev. Drug Discov. 10, 698–712. doi:
10.1038/nrd3505
Lublin, A. L., and Gandy, S. (2010). Amyloid-beta
oligomers: possible roles as key neurotoxins in
Alzheimer’s Disease. Mt. Sinai J. Med. 77, 43–49.
doi: 10.1002/msj.20160
Mattson, M. P. (2004). Pathways towards and away
from Alzheimer’s disease. Nature 430, 631–639.
doi: 10.1038/nature02621
Ritchie, C.W., Bush, A. I., Mackinnon, A., Macfarlane,
S., Mastwyk, M., MacGregor, L., et al. (2003).
Metal-protein attenuation with iodochlorhydrox-
yquin (clioquinol) targeting Abeta amyloid depo-
sition and toxicity in Alzheimer disease: a pilot
phase 2 clinical trial. Arch. Neurol. 60, 1685–1691.
doi: 10.1001/archneur.60.12.1685
Selkoe, D. J. (2008). Soluble oligomers of the amy-
loid beta-protein impair synaptic plasticity and
behavior. Behav. Brain Res. 192, 106–113. doi:
10.1016/j.bbr.2008.02.016
Stenh, C., Englund, H., Lord, A., Johansson, A.
S., Almeida, C. G., Gellerfors, P., et al. (2005).
Amyloid-beta oligomers are inefficiently measured
by enzyme-linked immunosorbent assay. Ann.
Neurol. 58, 147–150. doi: 10.1002/ana.20524
Conflict of Interest Statement: The authors declare
that the research was conducted in the absence of any
commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 13 June 2014; accepted: 25 July 2014;
published online: 13 August 2014.
Citation: Adlard PA, Li Q-X, McLean C, Masters
CL, Bush AI, Fodero-Tavoletti M, Villemagne V and
Barnham KJ (2014) β-amyloid in biological samples:
not all Aβ detection methods are created equal. Front.
Aging Neurosci. 6:203. doi: 10.3389/fnagi.2014.00203
This article was submitted to the journal Frontiers in
Aging Neuroscience.
Copyright © 2014 Adlard, Li, McLean, Masters, Bush,
Fodero-Tavoletti, Villemagne and Barnham. This is an
open-access article distributed under the terms of the
Creative Commons Attribution License (CC BY). The
use, distribution or reproduction in other forums is
permitted, provided the original author(s) or licen-
sor are credited and that the original publication
in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduc-
tion is permitted which does not comply with these
terms.
Frontiers in Aging Neuroscience www.frontiersin.org August 2014 | Volume 6 | Article 203 | 4
